Výsledky vyhledávání - "Richard S. Ungerleider"

Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors

Autor: Richard S. Ungerleider, Elisabeth I. Heath, Amy Weise, Ulka N. Vaishampayan, Yasuo Urata, Dailan Danforth

Publikováno v: Investigational New Drugs. 40:300-307

Background Dysregulation of histone deacetylases (HDACs) is common in cancer and is critical to the development and progression of the majority of tumors. This first-in-human Phase Ia study assessed the safety, efficacy, and pharmacokinetics (PK) of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44631b32dcccb6bc10b1631713c7e829
https://doi.org/10.1007/s10637-021-01180-9

Zobrazit plný text záznamu

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Autor: Vincent Chung, Henry J. Durivage, Fadi Braiteh, Donald A. Richards, Francis Johnson, John S. Kovach, Richard S. Ungerleider, Aaron S. Mansfield

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 23(13)

Purpose: To determine the MTD and to assess the safety, tolerability, and potential activity of LB-100, a first-in-class small-molecule inhibitor of protein phosphatase 2A (PP2A) in adult patients with progressive solid tumors. Experimental Design: L

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb66c63e3237e7a1eba0b37044ed1eac
https://pubmed.ncbi.nlm.nih.gov/28039265

Zobrazit plný text záznamu

Cooperative Cancer Trials

Autor: Richard S. Ungerleider, Larry Rubinstein

Publikováno v: Wiley StatsRef: Statistics Reference

The clinical trials cooperative group program was established by the US National Cancer Institute in 1955. The number of groups increased to 18 by 1985 and then decreased to 11. This article describes the work of the groups since the mid-1980s. It co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b73725b605636caae2996d6459ddd5ac
https://doi.org/10.1002/9781118445112.stat04986

Zobrazit plný text záznamu

Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma

Autor: Hung T. Khong, Richard S. Ungerleider, Sanjiv S. Agarwala, Robert H.I. Andtbacka, Adil Daud, Kenneth F. Grossmann, Merrick I. Ross, John T. Vetto, Matthew H. Taylor, Maki Tanaka, Rogerio I. Neves

Publikováno v: Journal of Clinical Oncology. 35:9510-9510

9510 Background: HF10 is a bioselected replication-competent oncolytic virus derived from HSV-1. Herein, we report the safety and efficacy data of HF10 + ipilimumab (ipi) combination treatment in a Phase II trial in melanoma. Methods: Key entry crite

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::96ceb51cc37583599086dc792a440f0c
https://doi.org/10.1200/jco.2017.35.15_suppl.9510

Zobrazit plný text záznamu

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute

Autor: Malcolm A. Smith, Larry Rubinstein, Edward L. Korn, Richard Simon, Richard S. Ungerleider

Publikováno v: Journal of Clinical Oncology. 15:2736-2743

PURPOSE To describe the rationale for independent data monitoring committees (DMCs) for National Cancer Institute (NCI)-sponsored phase III cooperative group clinical trials. DESIGN We review the necessity for interim monitoring of outcome data durin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e3af2528c1c284b9b444a406acc7b55
https://doi.org/10.1200/jco.1997.15.7.2736

Zobrazit plný text záznamu

Dose Intensity of Chemotherapy for Childhood Cancers

Autor: Malcolm A. Smith, Jeffrey S. Abrams, Edward L. Trimble, Richard S. Ungerleider

Publikováno v: The Oncologist. 1:293-304

Since the formulation of the “dose-intensity” concept of anticancer therapy in the mid-1980s, the concept that “more is better” has gained general acceptance among pediatric oncologists. However, recently published clinical trials results for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a7babf7193f03855d8a7df377ac5916
https://doi.org/10.1634/theoncologist.1-5-293

Zobrazit plný text záznamu

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

Publikováno v: Journal of Clinical Oncology. 14:18-24

PURPOSE To define more uniform criteria for risk-based treatment assignment for children with acute lymphoblastic leukemia (ALL), the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) sponsored a workshop in September 19

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e320a369b0cc617bc21c09059143d1
https://doi.org/10.1200/jco.1996.14.1.18

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání